中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (5): 858-861.doi: 10.3969/j.issn.1673-8225.2010.05.023

• 器官移植基础实验 basic experiments of organ transplantation • 上一篇    下一篇

贝那普利对腹膜透析大鼠腹膜纤维化的影响

李建飞1，温黎青1，刘伏友2，刘  虹2，彭佑铭2   

  1. 1柳州市人民医院肾内科，广西壮族自治区柳州市 545006；2中南大学湘雅二医院肾内科，湖南省长沙市 410011
  • 出版日期:2010-01-29 发布日期:2010-01-29
  • 通讯作者: 刘伏友，教授，中南大学湘雅二医院肾内科，湖南省长沙市 410011　 felh@medmail.com.cn
  • 作者简介:李建飞★，男，1975年生，湖南省桃江县人，汉族， 2006年中南大学肾脏病研究所毕业，硕士，主治医师，主要从事肾脏病及腹膜透析的研究。 woodljf@yahoo.com.cn

Effects of benazepril on peritoneal fibrosis in rats with peritoneal dialysis

Li Jian-fei1, Wen Li-qing1, Liu Fu-you2, Liu Hong2, Peng You-ming2   

  1. 1 Department of Nephrology, The People’s Hospital of Liuzhou, Liuzhou 　545001, Guangxi Zhuang Autonomous Region, China; 2 Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha  410011, Hunan Province, China
  • Online:2010-01-29 Published:2010-01-29
  • Contact: Liu Fu-you, Professor, Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China felh@medmail.com.cn
  • About author:Li Jian-fei★, Master, Attending Physician, Department of Nephrology, The People’s Hospital of Liuzhou, Liuzhou 　545001, Guangxi Zhuang Autonomous Region, China woodljf@yahoo.com.cn

PDF

483

被引次数

4

摘要：

背景：已经证实血管紧张素转换酶抑制剂可延缓多种器官的纤维化。在慢性肾病中能降低蛋白尿，延缓肾硬化；在肝硬化中能改善肝脏微循环，抑制肝纤维化，但在腹膜透析中的腹膜纤维化是否具有相同的作用？作者未查及此类报道。
目的：提出血管紧张素转换酶抑制剂贝那普利可以抑制腹膜透析治疗中腹膜纤维化的假设，并在实验过程中与正常组、模型组、阴性对照组比较。
方法：将40只大鼠按随机数字表分为4组，每组10只：正常对照组不予任何干预；生理盐水组腹腔注射生理盐水；腹膜透析组腹腔注射20 mL 42.5 g/L葡萄糖透析液；腹膜透析合并用药组在腹腔注射42.5 g/L葡萄糖腹膜透析液20 mL同时口服贝那普利片20 mg/(kg·d)。腹腔注射均为1次/d，疗程4周。4周后，测量超虑量；取大鼠壁层腹膜组织，VG法染色光学显微镜观察腹膜厚度。
结果与结论：40只大鼠中腹膜透析组2只死于腹膜炎，腹膜透析合并用药组1只不明原因死亡，共37只进入结果分析。与正常对照组、生理盐水组比较，腹膜透析组、腹膜透析合并用药组超滤量均显著下降(P均< 0.05)；与腹膜透析合并用药组比较，腹膜透析组超滤量明显减少(P < 0.05)。与正常对照组、生理盐水组、腹膜透析合并用药组比较，腹膜透析组腹膜厚度显著增加(P < 0.05)；腹膜透析合并用药组腹膜厚度较正常对照组明显增加(P < 0.05)。在大鼠维持性腹膜透析过程中，服用贝那普利能有效保护腹膜超滤功能，减轻腹膜纤维化程度。

关键词: 腹膜透析, 腹膜纤维化, 贝那普利, 血管紧张素转换酶抑制剂, 超滤

Abstract:

BACKGROUND: It has confirmed that angiotensin converting enzyme inhibitor benazepril can delay fibrosis of varied organs. However, whether benazepril has inhabited effect on peritoneal fibrosis in the process of peritoneal dialysis is poorly understood.
OBJECTIVE: It is assumed that benazepril could inhabit peritoneal fibrosis of peritoneum with peritoneal dialysis, in addition, to compare the effect to other mehods.
METHODS: All rats were randomly and evenly divided into 4 groups. There was no intervention in the control group; saline solution, and 20 mL 42.5 g/L Dianeal solution, was injected into rats in the saline solution and peritoneal dialysis groups; in the combination group, 20 mL 42.5 g/L Dianeal solution was injected combined with oral taken benazepril 20 mg/(kg·d). The intraperitoneal injection performed once a day, for 4 successive weeks. The ultrafiltration function was performed 4 weeks later. Meantime, Paraffin sections were cut and stained by Van Gieson to measure peritoneal thickness.
RESULTS AND CONCLUSION: Two rats in the peritoneal dialysis group and 1 rat in the combination group were dead. The remained 37 rats were included in the final analysis. Compared to the control and saline solution groups, the ultrafiltration volume of the peritoneal dialysis and combination groups were obviously decreased (P all < 0.05), especially notably decreased in the combination group (P < 0.05). Compared to the control group and saline solution groups, the peritoneal thickness was significantly elevated in the combination group, but not as much as in the peritoneal dialysis group (P < 0.05). In the long-term peritoneal dialysis rats, administration of benazepril can effectively protect the ultrofiltration function of peritoneum and delay the progression of peritoneal fibrosis.

中图分类号: